Alemtuzumab, also known as Campath, is a humanized monoclonal antibody (Campath-1H) that targets the 21to 28-kDa cell surface glycoprotein CD52. CD52 is expressed on the surface of normal and malignant B and T lymphocytes, NK cells, monocytes, macrophages, and tissues of the male reproductive system. Alemtuzumab is an IgG1 κ form with humanized variable and constant regions and CDRs from a rat monoclonal antibody, Campath-1G. It was first introduced in the US for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy.
216503-57-0
Post Buying Request-
-
Basic information
- Product Name: Alemtuzumab
- Synonyms: Alemtuzumab;Alemtuzumab (usan/inn);Campath (tn);D02802;MabCampath
- CAS NO:216503-57-0
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: Alemtuzumab(CAS DataBase Reference)
- NIST Chemistry Reference: Alemtuzumab(216503-57-0)
- EPA Substance Registry System: Alemtuzumab(216503-57-0)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 216503-57-0(Hazardous Substances Data)
216503-57-0 Suppliers
Recommended suppliers
216503-57-0 Usage
Uses
Used in Antineoplastic Applications:Alemtuzumab is used as an antineoplastic monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia (CLL) in patients who have been treated with alkylating agents and have failed fludarabine therapy. It binds to CD52, a nonmodulating antigen present on the surface of essentially all B and T lymphocytes, most monocytes, macrophages, and NK cells, and a subpopulation of granulocytes. The proposed mechanism of action is antibody-dependent lysis of leukemic cells following cell surface binding.
Used in Clinical Trials:
In a phase III clinical trial with 93 fludarabine-resistant CLL patients, treatment with alemtuzumab gave a positive response in 31 patients with 2 complete remissions and 29 partial remissions. This study demonstrated a higher response rate in patients having malignancy confined to the blood and bone marrow.
Used in Drug Delivery Systems:
Although not explicitly mentioned in the provided materials, alemtuzumab's use in drug delivery systems could potentially involve targeting specific cell types for the delivery of therapeutic agents, leveraging its specificity for CD52-expressing cells.
Brand Name:
Campath (Boehringer Ingelheim KG, Germany)
Originator
Cambridge University (UK)Clinical Use
Treatment of chronic lymphocytic leukaemia (CLL) not totally responsive to other treatment Induction therapy in renal transplantation Treatment of relapsing remitting multiple sclerosis (MS)Drug interactions
Potentially hazardous interactions with other drugs Other chemotherapy: do not give within 3 weeks of each other. Live vaccines: avoid for at least 12 months after treatment.Metabolism
The metabolic pathway of alemtuzumab has not been elucidated. Clearance decreases with repeated administration due to decreased receptor mediated clearance (loss of CD52 receptors in the periphery).Check Digit Verification of cas no
The CAS Registry Mumber 216503-57-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,6,5,0 and 3 respectively; the second part has 2 digits, 5 and 7 respectively.Calculate Digit Verification of CAS Registry Number 216503-57:
(8*2)+(7*1)+(6*6)+(5*5)+(4*0)+(3*3)+(2*5)+(1*7)=110
110 % 10 = 0
So 216503-57-0 is a valid CAS Registry Number.
216503-57-0Upstream product
216503-57-0Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 216503-57-0
Alemtuzumab
